Ultragenyx Pharmaceutical

RAREleader

Ultragenyx is a rare-disease biopharmaceutical company with multiple approved therapies and a gene therapy pipeline, focusing on metabolic and bone diseases with no or limited treatment options.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($652M)

靜態數據（加載即時財務…）

Crysvita Royalties + Direct (60%)

Other Products (40%)

業務部門構成與主要客戶

產品詳情

Mepsevii (MPS VII)18%

IV enzyme replacement therapy for mucopolysaccharidosis VII — ultra-rare metabolic disorder.

Crysvita (XLH / TIO)45%

Burosumab monoclonal antibody for X-linked hypophosphatemia, the most common inherited form of rickets.

GTX-102 / setrusumab (bone diseases)15%

Gene therapy pipeline targeting osteogenesis imperfecta (brittle bone disease) and related disorders.

UX111 / delandistrogene (UCD, other)22%

AAV gene therapy programs for rare liver-based metabolic disorders and DMD.

供應鏈關係

合作夥伴

kyowa

Crysvita (burosumab) co-development

影響: critical

宏觀與市場背景

헬스케어行業新聞

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

近期催化劑

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

AI 分析

點擊「取得 AI 分析」以獲得 Ultragenyx Pharmaceutical 的 AI 供應鏈分析。

企業資訊

總部

Novato, California, USA

成立時間

2010

員工人數

1,200

官網

ultragenyx.com

行業概況 — 헬스케어

行業新聞